Own Pain Relief Solution Store In Your City | Franchise Sales & Distribution Call us on 8691006638
Preventive anticoagulation plays a critical role in modern clinical care, particularly in reducing the risk of thromboembolic complications in surgical, cardiovascular, and immobilized patients. Low molecular weight heparins (LMWH) are widely recognized for their predictable anticoagulant response and improved safety profile in controlled clinical environments.
NADROBARA® (Nadroparin Injection) is developed by RAWIA INTERNATIONAL HEALTHCARE (RIHCA) in collaboration with leading pharmaceutical manufacturing partners and marketed through RAWIACARE. The 2850 IU strength is specifically designed for prophylactic anticoagulation, supporting healthcare professionals in delivering safe and effective thrombosis prevention across regional and international healthcare markets.
NADROBARA® 2850 IU (Nadroparin Calcium) is a low molecular weight heparin (LMWH) used for prophylactic anticoagulation in patients at risk of thromboembolic events. It acts by inhibiting factor Xa activity, reducing clot formation and maintaining stable blood flow.
This strength is commonly used in preventive treatment protocols, particularly in surgical patients, immobilized individuals, and those requiring controlled anticoagulant support.
| Specifications Table | |
| Parameter | Details |
| Brand Name | NADROBARA® |
| Generic Name | Nadroparin Calcium |
| Arabic Name | نادروبارا نادروبارين كالسيوم |
| Category | Anticoagulants |
| Therapeutic Area | Low Molecular Weight Heparin |
| Dosage Form | Prefilled Syringe |
| Strength | 2850 IU |
| Volume | 0.3 ml |
| Route | Subcutaneous (Anti-Xa) |
| Developed By | RIHCA |
| Platform Name | RAWIACARE / RAWIACARE GLOBAL |
| Prevention of Deep Vein Thrombosis (DVT) |
| Post-surgical thromboprophylaxis |
| Anticoagulant support in immobilized patients |
| Prevention of thromboembolic complications |
| Hospital-based preventive protocols |
| It is used for the prevention of thromboembolic conditions, especially in surgical and immobilized patients. |
| It inhibits factor Xa activity, reducing clot formation and supporting normal blood flow. |
| It is intended for patients requiring prophylactic anticoagulation under medical supervision. |
| Subcutaneous injection. |
| 2850 IU, 3800 IU, 5700 IU |
